Non-Alcoholic Fatty Liver Disease and Possibilities of Its Therapy (Review)

NAFLD is an urgent multidisciplinary problem, given its high prevalence worldwide, as well as its role in the development and progression of cardiometabolic disorders and cancer. The review analyzed current data regarding epidemiology, mechanisms of development of non-alcoholic fatty liver disease and current possibilities of its therapy. The problem of NAFLD is well understood. At the same time, new data are published regarding the mechanisms of its development, the impact on other metabolically associated diseases. This proves that a further search for new treatment regimens for such patients is necessary in order to improve the prognosis and reduce cardiometabolic risks. Particular attention in the review was paid to the possibilities of hepatoprotective therapy for hepatic steatosis.

1. Maevskaya M.V., Kotovskaya YU.V., Ivashkin V.T. et al. National Consensus for Physicians on the Management of Adult Patients with Nonalcoholic Fatty Liver Disease and Its Major Comorbidities. Therapeutic Archives. 2022; 94(2): 216-53. [in Russian]. https://doi.org/10.26442/00403660.2022.02.201363.

2. Nelidova AV, Livzan MA, Nikolaev NA et al. Cardiovascular disease and non-alcoholic fatty liver disease: the relationship and pathogenetic aspects of pharmacotherapy. Rational Pharmacotherapy in Cardiology. 2021;17(6):880-8. [in Russian]. https://doi.org/10.20996/1819-6446-2021-12-14.

3. Clinical guidelines. Non-alcoholic fatty liver disease. 2024. Ministry of Health of the Russian Federation: official website [in Russian]. URL: https://cr.minzdrav.gov.ru/view-cr/748_2 (accessed: 25.07.2025).

4. Evstifeeva SE, SHal’nova SA, Kucenko VA et al. Prevalence of non-alcoholic fatty liver disease in the working-age population: associations with sociodemographic indicators and behavioral risk factors (ESSE-RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356 [in Russian]. https://doi.org/10.15829/1728-8800-2022-3356.

5. Vinitskaya E.V., Sandler Yu.G., Bordin.D.S. A new paradigm of nonalcoholic fatty liver disease: phenotypic diversity of metabolically associated fatty liver disease. Effective Pharmacotherapy. 2020; 16(24): 54-63 [in Russian].

6. Best C.H., Hartroft W.S. Liver damage produced by feeding alcohol or sugar and its prevention by choline. Br. Med. J. 1949; 2(4635): 1002–1006.

7. Hanssen P. Enlargement of the liver in diabetes mellitus. JAMA. 1936; 106: 914–916.

8. Thaler H. The fatty liver and its pathogenetic relation to liver cirrhosis. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 1962; 335: 180–210.

9. Ludwig J., Viggiano T.R., McGill D.B., Ohet B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55(7): 434–438.

10. Maccalau A.J. New information for non-alcoholic fatty liver disease. J. Clin. Gastroenterology. 2002; 34: 255–262.

11. Nonalcoholic steatohepatitis clinical research network. Hepatology. 2003; 37(2): 244 p.

12. Krolevec TS. Livzan MA. Non-alcoholic fatty liver disease: digest 2021. Evidence-based gastroenterology. 2021;10(2):27–35. https://doi.org/10.17116/dokgastro20211002127 [in Russian].

13. Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 1998;114:842–845.

14. Maev IV, Andreev DN, Kucheryavyy YuA. Metabolically associated fatty liver disease. Moscow: Prima Print, 2021, 72 p. [in Russian]

15. Maev I.V., Kucheryavy Yu.A., Andreev D.N. Liver and biliary tract in metabolic syndrome: a manual for physicians. Moscow, 2020. 52 p. [in Russian)].

16. Tsukanov VV, Osipenko MF, Beloborodova EV et al. Practical aspects of clinical manifestations, pathogenesis and therapy of alcoholic liver disease and non-alcoholic fatty liver disease: Expert opinion. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(4):7–13. [In Russian]. DOI: 10.22416/1382-4376-2023-33-4-7-13

17. Halilova DM, Sahautdinova GM. On the role of intestinal microbiota in the pathogenesis and treatment of non-alcoholic fatty liver disease. The attending physician. 2024;5(27):48-56 [in Russian]. https://doi.org/10.51793/OS.2024.27.5.009

18. Habanin SA, Pchelin IYU. Metabolic disorders in men and women with non-alcoholic fatty liver disease. Juvenis scientia. 2020; 6(6): 18-32 [in Russian].

19. Drapkina OM, Korneeva ON, Ivashkin VT. Impact on abdominal obesity parameters in patients with metabolic syndrome: focus on adherence to dietary recommendations. The attending physician. 2010;7: 29–34 [in Russian].

20. Marchesini G., Day C.P., Dufour J.F. EASL-EASD-easo clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64 (6): 1388–1402. DOI: 10.1016/j.jhep.2015.11.004

21. Akasheva DU Drapkina O.M. The Mediterranean Diet: History, Key Components, Evidence of Benefits, and Possibility of Application in Russia. Rational Pharmacotherapy in Cardiology. 2020;16(2):307-316. DOI: 10.20996/1819–6446-2020-04-03 [in Russian].

22. Andreev KA, Skirdenko YUP, Nikolaev NA. Adherence to lifestyle modification in nonalcoholic fatty liver disease. Bulletin of Siberian Medicine. 2021; 20 (4): 112–122. [in Russian]. https://doi.org/10.20538/1682-0363-2021–4-112-122.

23. Lyalyukova EA, Druk IV, CHernysheva EN. Physical activity as a multitarget therapy for metabolically associated fatty liver disease. Attending Physician. 2022; 2 (25): 8-12. [in Russian]. DOI: 10.51793/OS.2022.25.2.001.

24. Cheng S., Ge J., Zhao C., et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liverdisease: A randomized controlled trial. Sci Rep. 2017;7(1):15952. DOI: 10.1038/s41598-017-16159-x.

25. Kravchenko SD, Kozlova NM, Tirikova OV. Antioxidants as potential biomarkers of non-alcoholic fatty liver disease stages. Baikal Medical Journal. 2023;2(4):24-32. [in Russian]. https://doi.org/10.57256/2949-0715-2023-4-24-32.

26. Lazebnik LB, Golovanova EV., Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology.2021;1(1):4-52 [in Russian]. DOI: 10.31146/1682-8658-ecg-185-1-4-52

27. Ando Y, Jou JH. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clin Liver Dis (Hoboken). 2021;17(1):23-8. DOI: 10.1002/cld.1045.

28. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46. DOI: 10.7326/0003-4819-142-1-200501040-00110.

29. Stelmakh V.V., Kovalenko A.L., Kozlov V.K. Efficacy of the drug “Remaxol, solution for infusions” in the treatment of patients with intrahepatic cholestasis syndrome in chronic diffuse liver diseases. Experimental and Clinical Gastroenterology. 2018; (4): 89-98 [in Russian].

30. Il’chenko L.YU, Okovityj S.V. Remaxol: mechanisms of action and use in clinical practice. Part 1. The Russian Archives of Internal Medicine. 2016; 6 (28): 16-21 [in Russian]. DOI 10.20514/2226-6704-2016-6-2-16-21.

31. Stel’mah VV, Kovalenko AL, Popova VB. Results of the multicenter, open-label, comparative, randomized phase III study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome associated with chronic diffuse liver disease. Therapeutic Archives. 2021; 93(12):1470– 1476. [in Russian]. DOI: 10.26442/00403660.2021.12.201266].

32. Filippova NV, Baryl’nik IuB, Shuldyakov AA. The efficacy of remaxol as a hepatoprotective agent in long-term psychopharmacotherapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):4346. [in Russian]. https://doi.org/10.17116/jnevro201911901143

33. Raikhelson KL, Kondrashina EA. Àdåmethionine in the treatment of fatigue in liver diseases:a system-atic review. Therapeutic Archive. 2019; 91 (2): 134–142. [in Russian]. DOI: 10.26442/00403660.2019.02.000130.

34. Maevskaya MV, Nadinskaya MYU, Lun’kov VD. The effect of ursodeoxycholic acid on inflammation, liver steatosis, liver fibrosis, and atherogenic factors in patients with nonalcoholic fatty liver disease: results of the USPEKH study. Russian Journal of Gastroenterology, Hepatology, and Proctology. 2019;29(6):22–29. [in Russian]. https://doi.org/10.22416/1382-4376-2019-29-6-22-29.

35. Pirogova IYU, Ufimceva IV. A clinical trial of Ursosan Forte in patients with non-alcoholic fatty liver disease and cholelithiasis (the KURS study). RMJ. Medical Review. 2022;6(5):213-220. [in Russian]. DOI: 10.32364/2587-6821-2022-6-5-213-22.

36. Wong C, Lee MH, Yaow CYL, Chin YH, Goh XL, Ng CH et al. GlucagonLike Peptide1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:609110. https://doi.org/10.3389/fendo.2021.609110.

37. Zhou H, Toshiyoshi M, Zhao W. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26):e33981. https://doi.org/10.1097/MD.0000000000033981.

38. Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441–451. https://doi.org/10.1111/bcp.14943.

39. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism: clinical guidel ines. Moscow; 2023. 103 p. https:// cr.minzdrav.gov.ru/recomend/752_1.] [in Russian].

40. Houttu V, Csader S, Nieuwdorp M. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr. 2021;8:716783. https://doi.org/10.3389/fnut.2021.716783

41. Dedov II, Mokrysheva NG, Melnichenko GA, et al. Obesity: Clinical Guidelines. M.; 2020. Access mode: https://cr.minzdrav.gov.ru/recomend/28_2. [in Russian].

42. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASLEASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004.

43. Younossi ZM, Ratziu V, Loomba R, et al. REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96. DOI: 10.1016/S0140-6736(19)33041-7

44. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebocontrolled phase 3 trial. Nat Med. 2023;29(11):2919-28. https://doi.org/10.1038/s41591-023-02603-1.